Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
Frequently asked questions
What sector does Solasia Pharma KK (4597) operate in?
Solasia Pharma KK belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Solasia Pharma KK (4597) current stock price?
As of the latest data, Solasia Pharma KK stock price is ¥33, with a previous close of ¥31. Solasia Pharma KK gained ¥2 in the last trading session, representing a 6.45% increase.
What is Solasia Pharma KK (4597) current market capitalization?
Solasia Pharma KK market cap is approximately 9.01 billion.
What is Solasia Pharma KK (4597) Earnings Per Share (EPS)?
The trailing EPS is -¥4.
What is Solasia Pharma KK (4597) EBITDA?
Solasia Pharma KK EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -296.00 million.
Does Solasia Pharma KK (4597) pay dividends?
No. Solasia Pharma KK does not pay a dividend.
What is Solasia Pharma KK (4597) beta (volatility) score?
Solasia Pharma KK has a beta of 1.210, suggesting it is more volatile than the market.
